Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.
Zhigang LiuJames L AlexanderKai Yee EngHajir IbraheimSulak AnandabaskaranAamir SaifuddinLaura ConstableRocio Castro SeoaneClaire M BewsheaRachel NiceAndrea D'MelloGareth R JonesSharmili BalarajahFrancesca FiorentinoShaji SebastianPeter M IrvingLucy C HicksHorace R T WilliamsAlexandra J KentRachel LingerMiles ParkesKlaartje KokKamal V PatelJulian P TeareDaniel M AltmannRosemary J BoytonAilsa L HartCharlie W LeesJames R GoodhandNicholas A KennedyKatrina M PollockTariq AhmadNick Powellnull nullPublished in: Journal of Crohn's & colitis (2023)
Vaccination in both the 2020-2021 and 2021-2022 seasons was associated with significantly higher antibody responses to influenza/A than no vaccination or vaccination in 2021-2022 alone. Infliximab and tofacitinib are associated with lower binding antibody responses to Influenza/A, similar to COVID-19 vaccine-induced antibody responses.